RUBY
Rubius Therapeutics, Inc. [RUBY] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RUBY Stock Summary
In the News
RUBY Financial details
Company Rating
-
Market Cap
5.16M
Income
-233.75M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
6
Optionable
No
Shortable
Yes
Earnings
26 Feb 2024
P/E
-0.04
Forward P/E
-
PEG
-0.02
P/S
-
P/B
0.34
P/C
-
P/FCF
-0.07
Quick Ratio
2.39
Current Ratio
2.54
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.59
EPS next Y
-
EPS next Q
-
EPS this Y
19.07%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-55.34%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-582%
ROE
-519%
ROC
-4.08%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0032-0.3763
52W High
-
52W Low
-
RSI
46
Rel Volume
7.59
Avg Volume
99.54K
Volume
755.86K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
2.208
-
-
Volatility
0.01%, 0.01%
Prev Close
-31.33%
Price
0.057
Change
-
Company Profile
- Volume Average 99.54K
- Market Capitalization 5.16M
- Employee 6
- CEO Dr. Laurence A. Turka M.D.
- Headquarters Cambridge,MA,US
- IPO Date 2018-07-18
-
Website
https://www.rubiustx.com 
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
